Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
While premium valuations often signal strong growth, they also set the stage for sharp corrections when investor sentiment cools. We examine three stocks where sky-high expectations may be outpacing fundamentals.
A four-advisor team managing $1 billion in client assets has left Merrill Lynch to join Raymond James' employee channel, underscoring the intensifying competition for top wealth management talent.
AMD stock fell sharply Friday following a report of potential delays to its next-generation MI450 AI chip, sparking a debate over whether the sell-off is an overreaction or a sign of deeper valuation concerns.
Saks Global is closing the majority of its Saks OFF 5TH discount locations, including the final two in Massachusetts, amid a corporate restructuring following its recent bankruptcy filing.
In a striking pivot, crypto giant Tether is now stockpiling over a ton of gold weekly in a fortified Swiss vault—a move echoing crypto's early days but signaling a profound shift towards traditional safe-havens as digital assets falter.
With its stock near 52-week highs, Western Digital prepares to unveil its AI-driven storage roadmap at a pivotal New York event, seeking to transition its narrative from cyclical recovery to structural growth.
While low-volatility stocks offer a haven in turbulent markets, their perceived safety can sometimes obscure underlying financial weaknesses. We examine three such stocks where calm trading patterns may not justify their current valuations or growth prospects.
While Lindian Resources shares have retreated 13% recently, company insiders who bought stock over the past year are sitting on substantial paper profits, with one executive's purchase now valued at over seven times its cost.
UN Secretary-General Antonio Guterres has issued a stark warning that the organization faces a severe liquidity crisis, with funds for its regular operations potentially running dry by July. The crisis is exacerbated by billions in unpaid dues, primarily from the United States.
Shares of Monolithic Power Systems (MPWR) have soared over 230% in five years, but new analysis suggests the semiconductor leader's stock may now be trading at a significant premium. Investors are weighing whether the rally has outpaced fundamentals.
As Appen announces a key governance change, its surging share price collides with deep long-term losses, forcing a hard look at whether this AI data play is a turnaround story or a value trap.
The ASX-listed miner's heavily discounted rights issue aims to shore up its balance sheet after a period of steep losses, but analysts are divided on whether the fresh capital marks a new beginning or merely delays deeper challenges.
Netflix shares face pressure as the streaming giant's 2026 revenue guidance signals a significant growth deceleration, even with its advertising business poised to double. Investor concerns are compounded by a potential multi-billion dollar acquisition.
The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
